Here, we found that patients with HER2-amplified LUAD showed higher immunogenicity, mainly manifested in PD-L1 expression at the mRNA and protein level, as well as tissue and blood TMB, in comparison with HER2-amplified breast and gastric cancers. The gene discussed is ERBB2; the disease is gastric cancer.